The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Autoren

  • Amy A. Kirkham
  • Neil D. Eves
  • Rob E. Shave
  • Kelcey A. Bland
  • Joshua Bovard
  • Karen A. Gelmon
  • Sean A. Virani
  • Don C. McKenzie
  • Eric J. Stöhr
  • Darren E.R. Waburton
  • Kristin L. Campbell

Externe Organisationen

  • University of Alberta
  • University of British Columbia
  • Cardiff Metropolitan University
  • Columbia University
Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
Seiten (von - bis)719-729
Seitenumfang11
FachzeitschriftBreast Cancer Research and Treatment
Jahrgang167
Ausgabenummer3
PublikationsstatusVeröffentlicht - Feb. 2018
Extern publiziertJa

Abstract

Purpose In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. Methods Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vig-orous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms. Results The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred. Conclusions An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT. / Kirkham, Amy A.; Eves, Neil D.; Shave, Rob E. et al.
in: Breast Cancer Research and Treatment, Jahrgang 167, Nr. 3, 02.2018, S. 719-729.

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Kirkham, A. A., Eves, N. D., Shave, R. E., Bland, K. A., Bovard, J., Gelmon, K. A., Virani, S. A., McKenzie, D. C., Stöhr, E. J., Waburton, D. E. R., & Campbell, K. L. (2018). The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT. Breast Cancer Research and Treatment, 167(3), 719-729. https://doi.org/10.1007/s10549-017-4554-4
Download
@article{e47628587460468ca1313203b9f7c666,
title = "The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT",
abstract = "Purpose In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. Methods Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vig-orous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms. Results The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred. Conclusions An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.",
keywords = "Breast cancer, Cardiotoxicity, Doxorubicin, Exercise, Treatment symptoms",
author = "Kirkham, {Amy A.} and Eves, {Neil D.} and Shave, {Rob E.} and Bland, {Kelcey A.} and Joshua Bovard and Gelmon, {Karen A.} and Virani, {Sean A.} and McKenzie, {Don C.} and St{\"o}hr, {Eric J.} and Waburton, {Darren E.R.} and Campbell, {Kristin L.}",
note = "Funding Information: Financial support This work was supported by an Anita Cochrane Memorial Fund Award from the British Columbia Cancer Foundation. AK was supported by the Canadian Institutes of Health Research. We also acknowledge the support of GE Healthcare. ",
year = "2018",
month = feb,
doi = "10.1007/s10549-017-4554-4",
language = "English",
volume = "167",
pages = "719--729",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

Download

TY - JOUR

T1 - The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms

T2 - a RCT

AU - Kirkham, Amy A.

AU - Eves, Neil D.

AU - Shave, Rob E.

AU - Bland, Kelcey A.

AU - Bovard, Joshua

AU - Gelmon, Karen A.

AU - Virani, Sean A.

AU - McKenzie, Don C.

AU - Stöhr, Eric J.

AU - Waburton, Darren E.R.

AU - Campbell, Kristin L.

N1 - Funding Information: Financial support This work was supported by an Anita Cochrane Memorial Fund Award from the British Columbia Cancer Foundation. AK was supported by the Canadian Institutes of Health Research. We also acknowledge the support of GE Healthcare.

PY - 2018/2

Y1 - 2018/2

N2 - Purpose In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. Methods Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vig-orous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms. Results The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred. Conclusions An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.

AB - Purpose In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. Methods Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vig-orous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms. Results The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred. Conclusions An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.

KW - Breast cancer

KW - Cardiotoxicity

KW - Doxorubicin

KW - Exercise

KW - Treatment symptoms

UR - http://www.scopus.com/inward/record.url?scp=85033496718&partnerID=8YFLogxK

U2 - 10.1007/s10549-017-4554-4

DO - 10.1007/s10549-017-4554-4

M3 - Article

C2 - 29110150

AN - SCOPUS:85033496718

VL - 167

SP - 719

EP - 729

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -

Von denselben Autoren